TranS1 Inc. Announces Coverage Milestone

TranS1 Inc. Announces Coverage Milestone

WILMINGTON, N.C., Feb. 11, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON),
a medical device company focused on designing, developing and marketing
products to treat degenerative conditions of the spine affecting the lumbar
region, announced today that the company estimates that the total number of
commercial and Federal Government lives covered for pre-sacral interbody
fusion now exceeds 50 million, a significant milestone for pre-sacral
interbody fusion coverage utilizing its proprietary AxiaLIF® implant. In
addition, Medicare represents another 50 million covered lives divided into 15
different jurisdictions that typically cover Category I Codes that have
assigned dollar values. CPT Code 22586, utilized for pre-sacral interbody
fusion, was assigned a value by Medicare in November 2012.

"We are pleased to see the acceptance of the pre-sacral interbody fusion
procedure in the payor community within the first six weeks of this year. This
trend is a reflection of the strong clinical evidence and the growing interest
for the procedure within the spine surgery community," stated Ken Reali,
TranS1's President and CEO. A list of payors currently covering the procedure
is available on TranS1's website.

About TranS1 Inc.

TranS1 is a medical device company focused on designing, developing and
marketing products to treat degenerative conditions of the spine affecting the
lumbar region. TranS1 currently markets the AxiaLIF® family of products for
single and multilevel lumbar fusion, the VEO^TM lateral access and interbody
fusion system, and the Vectre^TM posterior fixation system for lumbar fixation
supplemental to AxiaLIF fusion. TranS1 was founded in May 2000 and is
headquartered in Wilmington, North Carolina. For more information,
visitwww.trans1.com.

Forward Looking Statements

This press release includes statements relating to our efforts to gain
favorable coverage decisions for our products that are based on our current
beliefs and assumptions. These statements constitute "forward looking
statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934, and are intended to
qualify for the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond our control,
and which may cause results to differ materially from expectations. Factors
that could cause our results to differ materially from those described
include, but are not limited to, the pace of adoption of our product
technology by spine surgeons, the outcome of coverage and reimbursement
decisions by the government and third party payors, the success of our
continuing product development efforts, the effect on our business of existing
and new regulatory requirements and other economic and competitive factors.
For a discussion of the most significant risks and uncertainties associated
with TranS1's business, please review the Company's filings with the
Securities and Exchange Commission, including its Annual Report on Form 10-K
for the year ended December 31, 2011. You are cautioned not to place undue
reliance on these forward looking statements, whichare based on TranS1's
expectations as of the date of this press release and speak only as of the
date of this press release.We undertake no obligation to publicly update or
revise any forward looking statement, whether as a result of new information,
future events or otherwise.

CONTACT: TranS1 Inc.
         Investors:
         Joe Slattery, Executive Vice President
         and Chief Financial Officer
         910-332-1700
        
         Westwicke Partners
         Mark Klausner
         443-213-0501
         trans1@westwicke.com